Fig. 2

SRGN aggravates ischemic brain injury. A Flow chart demonstrating the operation of MCAO and the following rSRGN injection. B, C Representative images of TTC-stained brain sections (B) with the quantification of infarct volume (C) at 1 day or 3 days after MCAO and injection of control solvent (50% glycerol) or rSRGN (2.5 mg/ mL). n = 5 ~ 6 mice per group. D, E The modified neurological severity score (mNSS) (D) and grip strength (E) at 1 day or 3 days after MCAO. n = 13 ~ 14 mice for groups at 1 day and n = 11 mice for groups at 3 days after MCAO. F, G Representative immunofluorescence images (F) and quantification (G) of neuronal death based on FJB staining assay in the ipsilateral hemisphere of ischemia brains of control solvent or rSRGN-injected mice at 1 day after MCAO. Scale bar, 50 μm. H, I Representative images of TTC-stained brain sections (H) from Srgn-KO mice and their wild-type (WT) littermates with the quantification of infarct volume (I) at 1 day after MCAO. n = 8 mice for the WT group and n = 6 mice for the Srgn-KO group. J, K The modified neurological severity score (mNSS) (J) and grip strength (K) at 1 day or 3 days after MCAO. n = 11 mice for groups at 1 day and n = 6 ~ 7 mice for groups at 3 days after MCAO. L, M Representative immunofluorescence images (L) and quantification (M) of neuronal death based on FJB staining assay in the ipsilateral hemisphere of ischemia brains of WT controls or Srgn-KO mice at 1 day after MCAO. Scale bar, 50 μm. Data represented as mean ± SEM, * p < 0.05, ** p < 0.01